Samsung Bioepis to begin global phase-III trials for Avastin biosimilar - (The Korea Herald via NewsPoints Desk)

  • Samsung Bioepis plans to soon initiate global late-stage studies of SB8, its investigational biosimilar of Roche's Avastin, The Korea Herald reported.

  • According to the EU Clinical Trials Register, the 678-patient trial will take place across 10 countries in Europe, as well as Taiwan and Korea.

  • The drugmaker declined to confirm the exact starting date of the trial.

  • The company has already received clearance from Korea's Ministry of Food and Drug Safety to initiate Phase III trials.

To read more NewsPoints articles, click here.